SCHEMBL254930

SCHEMBL254930

Nc1ccn(C[C@H](O)CO)c(=O)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 4/20 0.58
SLC22A6 Q4U2R8 1/20 0.56
ADORA2A P29274 2/20 0.39
AHCY P23526 1/20 0.39
LMNA P02545 4/20 0.39
THRB P10828 1/20 0.39
MTOR P42345 1/20 0.39
MDM2 Q00987 1/20 0.39
NCOA1 Q15788 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39
PDE3A Q14432 3/20 0.37
CACNA1F O60840 2/20 0.37
ALB P02768 2/20 0.37
MAPT P10636 2/20 0.37
CACNA1D Q01668 2/20 0.37
CACNA1S Q13698 2/20 0.37
CACNA1C Q13936 2/20 0.37
POLB P06746 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PDE4D Q08499 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL155990 1.00 FGFR1 (0.58) FGFR1SLC22A6ADORA2AAHCYLMNA
SCHEMBL24420123 1.00 FGFR1 (0.58) FGFR1SLC22A6ADORA2AAHCYLMNA
SCHEMBL140792 0.86 FGFR1 (0.50) FGFR1SLC22A6LMNATHRBMTOR
SCHEMBL8621597 0.86 FGFR1 (0.50) FGFR1SLC22A6LMNATHRBMTOR
SCHEMBL18069556 0.86 FGFR1 (0.50) FGFR1SLC22A6LMNATHRBMTOR
SCHEMBL5180818 0.84 FGFR1 (0.55) FGFR1SLC22A6LMNATHRBMTOR
SCHEMBL14948806 0.83 FGFR1 (0.56) FGFR1SLC22A6LMNATHRBMTOR
SCHEMBL10049650 0.83 FGFR1 (0.56) FGFR1SLC22A6LMNATHRBMTOR
SCHEMBL7269776 0.82 FGFR1 (0.52) FGFR1SLC22A6ADORA2ALMNATHRB
SCHEMBL7269771 0.82 FGFR1 (0.52) FGFR1SLC22A6ADORA2ALMNATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240026358-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2024-01-25 US disclosed
US-20240026358-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2024-01-25 US disclosed
WO-2023220428-A1 COMPOSITIONS FOR EDITING ASS1 TRANSCRIPTS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-11-16 WO disclosed
WO-2023220440-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-11-16 WO disclosed
WO-2022099159-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2022-05-12 WO disclosed
CN-110845560-B Phenylalanine amidated nucleotide derivative and preparation method and application thereof 广东中科药物研究有限公司 2021-08-24 CN disclosed
CN-110845560-A Phenylalanine amidated nucleotide derivative and preparation method and application thereof 广东中科药物研究有限公司 2020-02-28 CN disclosed
EP-3020720-B1 PHOSPHONATE ESTER DERIVATIVES AND METHODS OF SYNTHESIS THEREOF CHIMERIX INC (US) 2018-09-19 EP disclosed
EP-2611818-B1 PHOSPHONATE ESTER DERIVATIVES AND METHODS OF SYNTHESIS THEREOF CHIMERIX INC (US) 2016-08-24 EP disclosed
EP-3020720-A1 PHOSPHONATE ESTER DERIVATIVES AND METHODS OF SYNTHESIS THEREOF Chimerix, Inc. (US) 2016-05-18 EP disclosed
US-20140046085-A1 Phosphonate Ester Derivatives and Methods of Synthesis Thereof CHIMERIX, INC. (US) 2014-02-13 US disclosed
US-8569321-B2 Phosphonate ester derivatives and methods of synthesis thereof CHIMERIX, INC. (US) 2013-10-29 US disclosed
EP-2611818-A2 PHOSPHONATE ESTER DERIVATIVES AND METHODS OF SYNTHESIS THEREOF Chimerix, Inc. (US) 2013-07-10 EP disclosed
WO-2012031045-A2 PHOSPHONATE ESTER DERIVATIVES AND METHODS OF SYNTHESIS THEREOF CHIMERIX, INC. (US) 2012-03-08 WO disclosed
WO-2012031045-A2 PHOSPHONATE ESTER DERIVATIVES AND METHODS OF SYNTHESIS THEREOF CHIMERIX, INC. (US) 2012-03-08 WO disclosed
US-8063209-B2 Phosphonyl ester conjugates as prodrugs TSRL, INC. (US) 2011-11-22 US disclosed
US-20090270618-A1 PHOSPHONYL ESTER CONJUGATES AS PRODRUGS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-10-29 US disclosed
EP-0574386-B1 NOVEL PROCESS FOR THE PREPARATION OF NUCLEOTIDES ACAD OF SCIENCE CZECH REPUBLIC (CZ) 2000-06-28 EP disclosed
US-5591852-A Process for the preparation of nucleotides INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) 1997-01-07 US disclosed
US-5476938-A Process for the preparation of nucleotides INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) 1995-12-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140046085-A1 Phosphonate Ester Derivatives and Methods of Synthesis Thereof PHOSPHO1, PIK3CA, PNP FGFR1 2756/4885SLC22A6 3161/4885ADORA2A 538/4885
US-20090270618-A1 PHOSPHONYL ESTER CONJUGATES AS PRODRUGS DNPEP, PHOSPHO1, TYMP FGFR1 1739/4885SLC22A6 986/4885ADORA2A 2278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.